Adenovirus-Based Single-Dose Vaccines for SARS-CoV-2: A Review

Adenovirus-Based Single-Dose Vaccines for SARS-CoV-2: A Review

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak has many unexpected implications, but the scientific community remains optimistic about overcoming these obstacles. Adenoviruses (Ad) are considered the most suitable vectors for transferring specific antigens to mammalian cel...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vivek P Chavda, Anita A. Mehta, Hajra Zafar, Faisal Raza, Ana Cláudia Paiva-Santos, Pankti C. Balar, Vasso Apostolopoulos, Lalitkumar Vora
Format:	Article
Language:	English
Published:	IMR Press 2025-07-01
Series:	Frontiers in Bioscience-Landmark
Subjects:	single-shot/dose vaccine sars-cov-2 adenovirus covid-19 janssen vaccine sputnik light vaccine convidicea ad26.cov2.s ad26
Online Access:	https://www.imrpress.com/journal/FBL/30/7/10.31083/FBL25094
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunological response and implications of Ad26.COV2. S (Janssen COVID-19 vaccine) vaccine in diabetic patients: a prospective cohort study in Ethiopia
by: Chala Kenenisa Edae, et al.
Published: (2025-05-01)

An observational post-authorization study to assess the effectiveness of a single dose Ad26.COV2.S for the prevention of COVID-19 using real-world data
by: Amelia Boehme, et al.
Published: (2024-12-01)

Real-world effectiveness of Ad26.COV2.S or BNT162b2 booster vaccines against severe COVID-19 in adults who received a primary dose of Ad26.COV2.S in South Africa during the Delta period: A retrospective cohort study using medical scheme data
by: L Fairall, et al.
Published: (2025-08-01)

Antibody Avidity Maturation Following Booster Vaccination with an Intranasal Adenovirus Salnavac Vaccine
by: Ekaterina A. Astakhova, et al.
Published: (2024-12-01)

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material
by: Archana Jastorff, et al.
Published: (2024-12-01)

An experience of scaling and intensifying the industrial production of the Gam-COVID-Vac vector adenovirus vaccine in the limiting conditions of the pandemic
by: A. N. Morozov, et al.
Published: (2022-12-01)

Dynamics of humoral immunity during natural SARS-CoV-2 infection and/or after vaccination with the ‘Sputnik V’ vaccine
by: A. V. Ivanov, et al.
Published: (2024-11-01)

Assessment of antibody levels in a population vaccinated with Sputnik V
by: Diego Gonzalez, et al.
Published: (2023-03-01)

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life
by: Tessa Hosman, et al.
Published: (2024-12-01)

Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice
by: Mo C, et al.
Published: (2025-08-01)

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial
by: Neil Goldstein, et al.
Published: (2024-12-01)

Vaccine effectiveness of JCOVDEN single-dose against COVID-19 hospitalisation in Europe: An id.DRIVE test-negative case-control study
by: Chloé Wyndham-Thomas, et al.
Published: (2025-05-01)

Immunological efficacy and tolerability of vaccination in patients with noncommunicable diseases
by: O. M. Drapkina, et al.
Published: (2022-04-01)

Thrombosis in unvaccinated and Gam-COVID-Vac-vaccinated patients with COVID-19
by: A. G. Moiseeva, et al.
Published: (2022-08-01)

Enhanced construction of a bivalent adenovirus-based vaccine for preventing childhood pathogens: Human respiratory syncytial virus and norovirus
by: Ying-Chin Chen, et al.
Published: (2025-04-01)

Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein
by: Debora Patricia Garanzini, et al.
Published: (2025-03-01)

Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China
by: Kai Wang, et al.
Published: (2024-12-01)

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study
by: Tiffany Dyu, et al.
Published: (2024-12-01)

The Coronavirus SARS-Cov-2: the Complexity of Infection Pathogenesis, the Search of Vaccines and Possible Future Pandemics
by: E. P. Kharchenko
Published: (2020-07-01)

Comprehensive review of fowl and duck adenovirus vaccines development: innovations, challenges, and future directions
by: Mohammad Farzad AFSHAR, et al.
Published: (2025-06-01)

Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants
by: Hengchun Li, et al.
Published: (2024-12-01)

The attitude of medical students to vaccination against COVID-19
by: V. A. Anokhin, et al.
Published: (2022-06-01)

Frequency of Observed Side Effects of "Sputnik V" Vaccine in Vaccinated People in Ardabil Province , 2021
by: Saeed Mashahadi, et al.
Published: (2025-01-01)

Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history
by: Rui Wang, et al.
Published: (2025-08-01)

Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials
by: Yue Liu, et al.
Published: (2025-12-01)

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2
by: Muralimanohara S. T. Murala, et al.
Published: (2025-04-01)

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024-12-01)

Longitudinal Characterization of SARS-CoV-2 Immunity in Hemodialysis Patients Post Omicron
by: Andrew H. Karaba, et al.
Published: (2025-02-01)

Efficacy of COVID-19 vaccination in organized group: results of a prospective study
by: I. O. Stoma, et al.
Published: (2023-01-01)

The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary?
by: Adam Tworek, et al.
Published: (2023-03-01)

Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine
by: Dandan Peng, et al.
Published: (2023-04-01)

Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults
by: Jung Hyuk Lee, et al.
Published: (2025-01-01)

Immunogenicity evaluation of Gam-COVID-Vac (Sputnik V)
by: I. A. Kirillov, et al.
Published: (2022-12-01)

Vaccines against Covid-19: the Comparative Estimates of Risks in Adenovirus Vectors
by: E. P. Kharchenko
Published: (2020-11-01)

Immunogenicity and protective efficacy of a multi-antigenic adenovirus-based vaccine candidate against Mycobacterium tuberculosis
by: Jin-Seung Yun, et al.
Published: (2025-01-01)

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
by: Raveen Rathnasinghe, et al.
Published: (2020-01-01)

Erratum: Immunogenicity and protective efficacy of a multi-antigenic adenovirus-based vaccine candidate against Mycobacterium tuberculosis
by: Frontiers Production Office
Published: (2025-05-01)

Trends of vaccination against COVID-19 among pregnant women in Siberia
by: N. V. Artymuk, et al.
Published: (2022-03-01)

COVID-19 Vaccine Hesitancy Among Various Segments of the Population in Turkey: A Literature Review
by: Sezer Okay
Published: (2025-01-01)

A timely update of global COVID-19 vaccine development
by: Linda S. Klavinskis, et al.
Published: (2020-01-01)